By Sabela Ojea

AstraZeneca PLC said Thursday that its Farxiga drug showed positive results from the Deliver and Dapa-HF Phase 3 trial in reducing the risk of cardiovascular death or worsening heart failure.

The Anglo-Swedish pharma giant said that the trial was conducted in patients suffering from heart failures with mildly reduced or preserved ejection fraction.

"The safety and tolerability profile of Farxiga in the Deliver Phase 3 trial were consistent with the well-established safety profile of the medicine," it added.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

May 05, 2022 02:42 ET (06:42 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Astrazeneca.